Skip to content

Study · Non-randomized trial · n = 125 · 2000

11 results

Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.

Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jiménez F, Foubert L and 17 more

Show all authors

Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM

Clinical endocrinology1 Nov 2000Cited by 62 (Europe PMC)

PMID11106918 (opens in a new tab)DOI10.1046/j.1365-2265.2000.01134.x (opens in a new tab)PepBankPUB-11106918
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In acromegaly, mean GH decreased from 9.6 +/- 1.3 mU/l on lanreotide to 6.8 +/- 1.0 mU/l after octreotide (P < 0.001).

    In plain wordsIn acromegaly, growth hormone decreased after the switch from lanreotide to octreotide.

    Peptide
    Octreotide
    Outcome
    DecreaseMean GH concentration
    Study

    n = 125

    Comparator
    previous lanreotide SR
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg once monthly · intramuscular · 3 monthsAs given in this study (human).

    Measurements

    Mean GH concentration
    9.6 mU/l
    last evaluation on lanreotide SR (± 1.3)
    Mean GH concentration
    6.8 mU/l
    after three injections of octreotide LAR (± 1.0)
    P value
    < 0.001 p-value
    GH change after switch to octreotide LAR

    Source sentences

    Summary
    The mean GH concentration decreased from 9.6 +/- 1.3 mU/l at the last evaluation on lanreotide SR to 6.8 +/- 1.0 mU/l after three injections of octreotide LAR (P < 0.001).
    2 context sentences
    Summary · context
    A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26 medical centres in France, Spain and Germany were studied.
    Summary · context
    All patients were switched from lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In acromegaly, mean GH was 9.6 +/- 1.3 mU/l on lanreotide versus 6.8 +/- 1.0 mU/l after octreotide (P < 0.001).

    In plain wordsIn acromegaly, growth hormone was higher on lanreotide than after the switch to octreotide.

    Peptide
    Lanreotide
    Outcome
    IncreaseMean GH concentration
    Study

    n = 125

    Comparator
    subsequent octreotide LAR
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    30 mg every 10 or 14 days · intramuscular · mean 26 monthsAs given in this study (human).

    Measurements

    Mean GH concentration
    9.6 mU/l
    last evaluation on lanreotide SR (± 1.3)
    Mean GH concentration
    6.8 mU/l
    after three injections of octreotide LAR (± 1.0)
    P value
    < 0.001 p-value
    GH change after switch to octreotide LAR

    Source sentences

    Summary
    The mean GH concentration decreased from 9.6 +/- 1.3 mU/l at the last evaluation on lanreotide SR to 6.8 +/- 1.0 mU/l after three injections of octreotide LAR (P < 0.001).
    2 context sentences
    Summary · context
    A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26 medical centres in France, Spain and Germany were studied.
    Summary · context
    All patients were switched from lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In acromegaly, GH at or below 6.5 mU/l increased from 54% on lanreotide to 68% after octreotide (P < 0.001).

    In plain wordsIn acromegaly, more patients had growth hormone at or below 6.5 mU/l after octreotide than on lanreotide.

    Peptide
    Octreotide
    Outcome
    IncreaseGH at or below 6.5 mU/l
    Study

    n = 125

    Comparator
    previous lanreotide SR
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg once monthly · intramuscular · 3 monthsAs given in this study (human).

    Measurements

    Patients with mean GH <= 6.5 mU/l (2.5 microg/l)
    54%
    last evaluation on lanreotide SR
    Patients with mean GH <= 6.5 mU/l (2.5 microg/l)
    68%
    after 3 months of octreotide LAR
    P value
    < 0.001 p-value
    increase after switch to octreotide LAR

    Source sentences

    Summary
    The percentages of patients with mean GH values < or = 6.5 mU/l (2.5 microg/l) and < or = 2.6 mU/l (1.0 microg/l) at the last evaluation on lanreotide SR were 54% and 14%, and these values increased after 3 months treatment with octreotide LAR to 68% and 35% (P < 0.001), respectively.
    2 context sentences
    Summary · context
    A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26 medical centres in France, Spain and Germany were studied.
    Summary · context
    All patients were switched from lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months.
  4. 04HumanNon-randomized trialEfficacy outcome

    In acromegaly, GH at or below 6.5 mU/l occurred in 54% on lanreotide versus 68% after octreotide (P < 0.001).

    In plain wordsIn acromegaly, fewer patients had growth hormone at or below 6.5 mU/l on lanreotide than after octreotide.

    Peptide
    Lanreotide
    Outcome
    DecreaseGH at or below 6.5 mU/l
    Study

    n = 125

    Comparator
    subsequent octreotide LAR
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    30 mg every 10 or 14 days · intramuscular · mean 26 monthsAs given in this study (human).

    Measurements

    Patients with mean GH <= 6.5 mU/l (2.5 microg/l)
    54%
    last evaluation on lanreotide SR
    Patients with mean GH <= 6.5 mU/l (2.5 microg/l)
    68%
    after 3 months of octreotide LAR
    P value
    < 0.001 p-value
    increase after switch to octreotide LAR

    Source sentences

    Summary
    The percentages of patients with mean GH values < or = 6.5 mU/l (2.5 microg/l) and < or = 2.6 mU/l (1.0 microg/l) at the last evaluation on lanreotide SR were 54% and 14%, and these values increased after 3 months treatment with octreotide LAR to 68% and 35% (P < 0.001), respectively.
    2 context sentences
    Summary · context
    A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26 medical centres in France, Spain and Germany were studied.
    Summary · context
    All patients were switched from lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months.
  5. 05HumanNon-randomized trialEfficacy outcome

    In acromegaly, GH at or below 2.6 mU/l increased from 14% on lanreotide to 35% after octreotide (P < 0.001).

    In plain wordsIn acromegaly, more patients had growth hormone at or below 2.6 mU/l after octreotide than on lanreotide.

    Peptide
    Octreotide
    Outcome
    IncreaseGH at or below 2.6 mU/l
    Study

    n = 125

    Comparator
    previous lanreotide SR
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg once monthly · intramuscular · 3 monthsAs given in this study (human).

    Measurements

    Patients with mean GH <= 2.6 mU/l (1.0 microg/l)
    14%
    last evaluation on lanreotide SR
    Patients with mean GH <= 2.6 mU/l (1.0 microg/l)
    35%
    after 3 months of octreotide LAR
    P value
    < 0.001 p-value
    increase after switch to octreotide LAR

    Source sentences

    Summary
    The percentages of patients with mean GH values < or = 6.5 mU/l (2.5 microg/l) and < or = 2.6 mU/l (1.0 microg/l) at the last evaluation on lanreotide SR were 54% and 14%, and these values increased after 3 months treatment with octreotide LAR to 68% and 35% (P < 0.001), respectively.
    2 context sentences
    Summary · context
    A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26 medical centres in France, Spain and Germany were studied.
    Summary · context
    All patients were switched from lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months.
  6. 06HumanNon-randomized trialEfficacy outcome

    In acromegaly, GH at or below 2.6 mU/l occurred in 14% on lanreotide versus 35% after octreotide (P < 0.001).

    In plain wordsIn acromegaly, fewer patients had growth hormone at or below 2.6 mU/l on lanreotide than after octreotide.

    Peptide
    Lanreotide
    Outcome
    DecreaseGH at or below 2.6 mU/l
    Study

    n = 125

    Comparator
    subsequent octreotide LAR
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    30 mg every 10 or 14 days · intramuscular · mean 26 monthsAs given in this study (human).

    Measurements

    Patients with mean GH <= 2.6 mU/l (1.0 microg/l)
    14%
    last evaluation on lanreotide SR
    Patients with mean GH <= 2.6 mU/l (1.0 microg/l)
    35%
    after 3 months of octreotide LAR
    P value
    < 0.001 p-value
    increase after switch to octreotide LAR

    Source sentences

    Summary
    The percentages of patients with mean GH values < or = 6.5 mU/l (2.5 microg/l) and < or = 2.6 mU/l (1.0 microg/l) at the last evaluation on lanreotide SR were 54% and 14%, and these values increased after 3 months treatment with octreotide LAR to 68% and 35% (P < 0.001), respectively.
    2 context sentences
    Summary · context
    A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26 medical centres in France, Spain and Germany were studied.
    Summary · context
    All patients were switched from lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months.
  7. 07HumanNon-randomized trialEfficacy outcome

    In acromegaly, normal IGF-I increased from 48% on lanreotide to 65% after 3 months on octreotide (P < 0.001).

    In plain wordsIn acromegaly, more patients had normal IGF-I after octreotide than on lanreotide.

    Peptide
    Octreotide
    Outcome
    IncreaseIGF-I normalization
    Study

    n = 125

    Comparator
    previous lanreotide SR
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg once monthly · intramuscular · 3 monthsAs given in this study (human).

    Measurements

    Patients with normal IGF-I
    48%
    last evaluation on lanreotide SR
    Patients with normal IGF-I
    65%
    after 3 months of octreotide LAR
    P value
    < 0.001 p-value
    increase after switch to octreotide LAR

    Source sentences

    Summary
    IGF-I levels were normal in 48% at the last evaluation on lanreotide SR and in 65% after 3 months on octreotide LAR (P < 0.001).
    2 context sentences
    Summary · context
    A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26 medical centres in France, Spain and Germany were studied.
    Summary · context
    All patients were switched from lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months.
  8. 08HumanNon-randomized trialEfficacy outcome

    In acromegaly, IGF-I was normal in 48% on lanreotide versus 65% after 3 months on octreotide (P < 0.001).

    In plain wordsIn acromegaly, fewer patients had normal IGF-I on lanreotide than after octreotide.

    Peptide
    Lanreotide
    Outcome
    DecreaseIGF-I normalization
    Study

    n = 125

    Comparator
    subsequent octreotide LAR
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    30 mg every 10 or 14 days · intramuscular · mean 26 monthsAs given in this study (human).

    Measurements

    Patients with normal IGF-I
    48%
    last evaluation on lanreotide SR
    Patients with normal IGF-I
    65%
    after 3 months on octreotide LAR

    Source sentences

    Summary
    IGF-I levels were normal in 48% at the last evaluation on lanreotide SR and in 65% after 3 months on octreotide LAR (P < 0.001).
    2 context sentences
    Summary · context
    A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26 medical centres in France, Spain and Germany were studied.
    Summary · context
    All patients were switched from lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months.
  9. 09HumanNon-randomized trialSafety outcome

    In acromegaly, lanreotide was generally well tolerated.

    In plain wordsIn acromegaly, patients generally tolerated lanreotide well.

    Peptide
    Lanreotide
    Outcome
    Not applicableTolerability
    Study

    n = 125

    Outcome group
    Adverse events · Whole body
    Studied dose
    30 mg every 10 or 14 days · intramuscularAs given in this study (human).

    Source sentences

    Summary
    In general both drugs were well tolerated.
    2 context sentences
    Summary · context
    A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26 medical centres in France, Spain and Germany were studied.
    Summary · context
    All patients were switched from lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months.
  10. 10HumanNon-randomized trialSafety outcome

    In acromegaly, octreotide was generally well tolerated.

    In plain wordsIn acromegaly, patients generally tolerated octreotide well.

    Peptide
    Octreotide
    Outcome
    Not applicableTolerability
    Study

    n = 125

    Outcome group
    Adverse events · Whole body
    Studied dose
    20 mg once monthly · intramuscularAs given in this study (human).

    Source sentences

    Summary
    In general both drugs were well tolerated.
    2 context sentences
    Summary · context
    A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26 medical centres in France, Spain and Germany were studied.
    Summary · context
    All patients were switched from lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months.
  11. 11HumanObservational studyEfficacy outcome

    In acromegaly, effects of the switch from lanreotide to octreotide did not differ between irradiated and nonirradiated patients.

    In plain wordsIn acromegaly, the switch to octreotide had similar effects in patients with and without previous pituitary irradiation.

    Peptide
    Octreotide
    Outcome
    No significant changeTreatment effects by irradiation history
    Study

    n = 125

    Comparator
    nonirradiated patients
    Outcome group
    Overall treatment effect · Endocrine and hormones
    Studied dose
    20 mg once monthly · intramuscular · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    But the effects of the treatment change did not differ between the irradiated and the nonirradiated patients.
    3 context sentences
    Summary · context
    Patients with pre-study pituitary irradiation had lower mean GH and IGF-I concentrations.
    Summary · context
    A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26 medical centres in France, Spain and Germany were studied.
    Summary · context
    All patients were switched from lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.